Ibrahim S. Alhomoud

Dr. Ibrahim S. Alhomoud

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2023 in Current Hypertension Reports
Verified
Journal Article
Closed access
PDF file
SCStacey Cutrell
Stacey Cutrell
Ibrahim S. AlhomoudIbrahim S. Alhomoud
Ibrahim S. Alhomoud
AMAnurag Mehta
Anurag Mehta
ATAzita H. Talasaz
Azita H. Talasaz
BTBenjamin Van Tassell
Benjamin Van Tassell
DDDave L. Dixon
Dave L. Dixon

26 July 2023 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Open access
Ibrahim S. AlhomoudIbrahim S. Alhomoud
Ibrahim S. Alhomoud
ATAzita Talasaz
Azita Talasaz
AMAnurag Mehta
Anurag Mehta
MKMichael S. Kelly
Michael S. Kelly
ESEvan M. Sisson
Evan M. Sisson
DDDave L. Dixon
Dave L. Dixon
Lipoprotein(a), or Lp(a), is structurally like low‐density lipoprotein (LDL) but differs in that it contains glycoprotein apolipoprotein(a) [apo(a)]. Due to its prothrombotic and proinflammatory properties, Lp(a) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis. Lp(a) levels are genetically determined, and it is estimated that 20%–25% of the global population has an Lp(a) level ≥50 mg/dL (or ≥125 nmol/L). Diet and lifestyle interventions have little to no effect on Lp(a) levels. Lipoprotein apheresis is the only approved treatment for elevated Lp(a) but is time‐intensive for the patient and only modestly effective. Pharmacological approaches to reduce Lp(a) levels and its associated risks are of significant interest; however, currently available lipid‐lowering therapies have limited effectiveness in reducing Lp(a) levels. Although statins are first‐line agents to reduce LDL cholesterol levels, they modestly increase Lp(a) levels and have not been shown to change Lp(a)‐mediated ASCVD risk. Alirocumab, evolocumab, and inclisiran reduce Lp(a) levels by 20‐25%, yet the clinical implications of this reduction for Lp(a)‐mediated ASCVD risk are uncertain. Niacin also lowers Lp(a) levels; however, its effectiveness in mitigating Lp(a)‐mediated ASCVD risk remains unclear, and its side effects have limited its utilization. Recommendations for when to screen and how to manage individuals with elevated Lp(a) vary widely between national and international guidelines and scientific statements. Three investigational compounds targeting Lp(a), including small interfering RNA (siRNA) agents (olpasiran, SLN360) and an antisense oligonucleotide (pelacarsen), are in various stages of development. These compounds block the translation of messenger RNA (mRNA) into apo(a), a key structural component of Lp(a), thereby substantially reducing Lp(a) synthesis in the liver. The purpose of this review is to describe current recommendations for screening and managing elevated Lp(a), describe the effects of currently available lipid‐lowering therapies on Lp(a) levels, and provide insight into emerging therapies targeting Lp(a).

3 September 2024 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
Ibrahim S. AlhomoudIbrahim S. Alhomoud
Ibrahim S. Alhomoud
ATAzita H. Talasaz
Azita H. Talasaz
PCPreethi Chandrasekaran
Preethi Chandrasekaran
RBRoy Brown
Roy Brown
AMAnurag Mehta
Anurag Mehta
DDDave L. Dixon
Dave L. Dixon

2 June 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
Ibrahim S. AlhomoudIbrahim S. Alhomoud
Ibrahim S. Alhomoud
MAMohamed A. Albekery
Mohamed A. Albekery
RARazan Alqadi
Razan Alqadi
AAAmal Alqumia
Amal Alqumia
RKRiaz A. Khan
Riaz A. Khan
MMMohammed Yousef Al Mulhim
Mohammed Yousef Al Mulhim
Diabetic kidney disease (DKD) represents a substantial health burden for patients with type 2 diabetes mellitus (T2DM), markedly increasing morbidity and mortality. The cornerstone of DKD treatment remains renin-angiotensin system (RAS) blockade and risk factor control, such as blood pressure management, glycemic control, albuminuria reduction, and lipid management. However, treatment strategies have expanded to include sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, which have proven effective in slowing kidney disease progression when combined with RAS inhibitors. Finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), represents a novel approach to the management of DKD. It offers unique pharmacokinetic and pharmacodynamic properties compared with steroidal MRAs such as spironolactone and eplerenone. This review addresses the evolving landscape of diabetic kidney disease management, with a focus on finerenone’s distinct pharmacologic properties, structural characteristics, and clinical implications.

27 February 2024 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
Ibrahim S. AlhomoudIbrahim S. Alhomoud
Ibrahim S. Alhomoud
ECEmily Cook
Emily Cook
DPDhruv Patel
Dhruv Patel
RBRoy E. Brown
Roy E. Brown
DDDave L. Dixon
Dave L. Dixon

13 September 2024 in Healthcare
Verified
Journal Article
Open access
PDF file
Ibrahim S. AlhomoudIbrahim S. Alhomoud
Ibrahim S. Alhomoud
AAAlian Alrasheedy
Alian Alrasheedy
Burnout has negative consequences for the well-being of healthcare professionals and for the safety of patients. The prevalence of burnout varies among health professions and practice settings and across studies. Consequently, this cross-sectional study aimed to determine the prevalence and factors associated with burnout among community pharmacists in the Qassim region, Saudi Arabia. The study used the Copenhagen Burnout Inventory (CBI) to assess the burnout. The CBI consists of three scales, including personal burnout, work-related burnout, and client-related burnout. A total of 226 community pharmacists participated in the study. Of these, 63.72% were male, and 44.25% had experience of 1–5 years as community pharmacists. The prevalence of personal burnout was 83.63%, while the prevalence of work-related burnout was 83.19%, and the prevalence of client-related burnout was 76.11%. The prevalence of burnout was higher among younger age, early-career pharmacists; staff pharmacists; pharmacists working ≥6 days per week; and those working in pharmacies with fewer pharmacy teams. Multivariable logistic regression showed that compared to five workdays, working six and seven days per week was an independent risk factor for developing personal burnout [(adjusted odds ratio (aOR) = 3.60: CI = (1.29–10.05), p = 0.014) and (aOR = 4.72: CI = (1.17–19.08), p = 0.030), respectively]. Similarly, pharmacists working in pharmacies with one or two pharmacists were at higher odds of developing personal burnout compared to others working in a larger team (aOR = 3.41: CI = (1.09–10.66), p = 0.035). For work-related burnout, working six and seven days per week was also an independent risk factor [(aOR = 5.78: CI = (1.96–17.06), p = 0.001), and (aOR = 8.38: CI = (1.99–35.27), p = 0.004, respectively)]. For client-related burnout, staff pharmacists were at higher odds of developing client-related burnout compared to pharmacy managers [(aOR = 2.28: CI = (1.01–5.14), p = 0.046)]. Overall, the prevalence of burnout is alarmingly high among community pharmacists in Saudi Arabia. Consequently, it is crucial to urgently address it through robust initiatives, strategies, and interventions that support the well-being, quality of life, and resilience of community pharmacists.